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Summary
Multiple sclerosis (MS) is the most common inflammatory
demyelinating disorder of the central nervous system
(CNS). Over the past 10 years there has been a heated
debate as to whether MS pathogenesis commences in the
CNS or whether it is actually primarily a disease of the
immune system. The combined clinical data, therapy re-
sponses, pathology, animal models and genetic studies now
provide overwhelming support for the concept that MS is a
disease of the immune system and that the CNS is only the
unfortunate target of a misguided immune attack.
Immune cells communicate through the use of cytokines
and these proteins can orchestrate the most complex beha-
viour in immune cells. We propose that MS is a disease
where immune communication is derailed, which makes
MS very amenable to immunotherapy and in particular
makes cytokines an attractive target to repair this miscom-
munication disorder.
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Abbreviations
APRIL a proliferation-inducing ligand
BAFF B cell activation factor
BlyS B lymphocyte stimulator
CNS central nervous system
CSF cerebrospinal fluid
EAE experimental autoimmune encephalomyelitis
GM-CSF granulocyte-macrophage colony-stimulating factor
IFN interferon
Ig immunoglobulin
IL interleukin
mAbs monoclonal antibodies
MHC major histocompatibility complex
MS multiple sclerosis
NK cells natural killer cells
NMO neuromyelitis optica
TGF transforming growth factor
Th cell T helper cell
TNF tumour necrosis factor
Introduction
Cytokines are small proteins that permit immune cells to
communicate with each other and their surrounding tissue.
They represent the “words” in the complex language of the
immune system and are therefore critical to coordination of
immune functions. Different classes of cytokines have his-
torically been categorised into interleukins (ILs), interfer-
ons (IFNs), growth factors, chemokines and tumour nec-
rosis factors (TNFs). In all groups combined, more than
400 members of the greater cytokine family are independ-
ently recognised and studied. Multiple functions can be at-
tributed to each of these mediators, a phenomenon broadly
termed “pleiotropy”, which when extrapolated results in a
vast range of responses controlled by cytokines, including
cell proliferation, migration, fibrosis, repair, angiogenesis,
immunity and inflammation [1, 2].
Deregulated cytokine responses are observed across all
chronic inflammatory diseases and immunopathologies,
and there are strong indications from genome-wide associ-
ation studies that cytokine deregulation is a driver of the
pathogenesis. Here, we will discuss current understand-
ing of the role of cytokines in multiple sclerosis (MS), an
autoimmune demyelination disease that can affect the brain
and spinal cord (CNS). As there are far too many cytokines
involved in the pathogenesis of MS to be covered in this
review article, representative examples of the most prom-
inent cytokines as therapeutic targets in MS are discussed.
Background
In the 1960s and 1970s, researchers became aware of mul-
tiple soluble factors in cell supernatants, distinguished from
each other by bioactivity assays, for example “T cell
growth factor” [3]. Another example is tumour necrosis
factor (TNF), which was described as a mediator of
lipopolysaccharide-induced necrosis of transplantable tu-
mours [4]. In the late 1970s, the field of cytokine biology
came of age with the introduction of molecular approaches
that resulted in the first successful cloning of cytokines
such as type I IFNs [5–7]. By the mid-1980s, there was a
plethora of well-characterised cytokines and receptors that
could be studied with use of molecular tools such as mono-
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clonal antibodies that had revolutionised the ability to spe-
cifically recognise a given protein.
Today different therapeutic strategies are used to restore
or reduce cytokine signalling pathways in vivo. Purified
recombinant cytokines can be administered, for example
haematopoietic growth factors (colony stimulating factors)
and IFNs. Second, therapeutic agents that inhibit the harm-
ful effects of deregulated proinflammatory cytokines have
been developed. The most established methods to neutral-
ise unwanted cytokine signalling are monoclonal antibod-
ies (mAbs), soluble receptors or receptor-Fc fusion molec-
ules and cytokine antagonists. To lower the immunogeni-
city of murine monoclonal antibodies (generated in rodent
species), therapeutic antibodies used in clinical practice
are “humanised” by replacing the rodent immunoglobulin
structures with human counterparts [8]. Soluble receptor
antagonists are usually truncated forms of the cell surface
receptor that are devoid of the transmembrane and in-
tracytoplasmic domains but still can bind the cytokine. So-
metimes these receptors are fused to the Fc portion of hu-
man immunoglobulins (Igs) to further enhance the stability
and half-life of the antibody.
First indications that cytokine pathways are implicated in
MS pathogenesis were the results of genetic studies that re-
ported an association of MS disease with certain cytokine
and receptor genes (IL7Ra, IL2Ra and others) [9–12]. In
patients with MS and in experimental mouse models of MS
(in particular experimental autoimmune encephalomyelit-
is, EAE), altered patterns of cytokine expression by vari-
ous immune cells are observed in the periphery and the
CNS, which will be discussed in more detail below. Thus,
it was assumed that the balance between pro- and anti-in-
flammatory cytokines regulates the development and pro-
gression of CNS inflammation and tissue damage. Clin-
ical evidence that cytokines are functionally involved in
MS in terms of clinical activity was initially based on a
clinical trial in which administration of IFN-γ exacerbated
the disease [13]. This established a presumptive pathogenic
role for IFN-γ-producing, CD4+ T helper (Th) 1 cells, and
these Th1 cells and their most abundant cytokines, such as
IFN-γ, TNF-α and the Th1-polarising, antigen-presenting
cell-derived molecule IL-12 were considered the primary
disease mediators of neuroinflammation. Subsequent stud-
ies in MS and EAE indicated that this view is most likely
overly simplistic, and that additional pathogenic T cell sub-
sets with different cytokine profiles as well as “innate” cy-
tokines (IL-1, IL-6, TNF-α, type I IFNs, etc.) secreted by
innate immune cells and stroma might have important ef-
fects within inflamed CNS tissue.
In addition to the aforementioned studies, a great deal of re-
search in preclinical disease models and patients has high-
lighted deregulated cytokine signals as a primary instigator
of pathogenesis in EAE and MS. Therefore, multiple at-
tempts have been made to treat MS patients with recom-
binant anti-inflammatory cytokines, or inhibitors of proin-
flammatory cytokines. It became clear very early that cy-
tokine networks are more complex than anticipated and
that individual cytokines may have diverse and even op-
posing functions in different clinical scenarios. With regard
to MS, despite the best efforts there is only one approved
cytokine therapy to date, which is IFN-β. Here we not only
focus on drugs in development but also briefly discuss sev-
eral treatment failures which one must better understand
mechanistically before successfully and safely applying
cytokine-directed therapies to MS patients in daily practice.
Approved cytokine therapies for MS:IFN-β
Type I IFNs were first characterised in 1957, and named for
their first observed biological effect: prevention of, or “in-
terference” during, viral infection [14]. Since then, it has
been shown that the effects of type I IFNs are much more
pleiotropic, and they are now appreciated for their roles not
just as anti-viral agents, but also as immune modulators and
cell growth regulators [15]. The connection between type
I IFNs and MS, as well as other autoimmune disorders, is
well known. Indeed, IFN-β has been extensively investig-
ated in EAE and MS and is the focus of numerous studies
found in the literature.
IFN-β-deficient mice are more susceptible to EAE [16] and
type I IFNs can attenuate EAE in mice [17], suggesting that
IFN-β inhibits immune-mediated demyelination in this MS
model. During EAE, elevated IFN-β concentrations can be
measured in the CNS but not blood [104], and intrathecal
application of the synthetic double-stranded RNA analogue
Figure 1
Key cytokines in the pathogenesis of multiple sclerosis.
In patients with MS and in its experimental models EAE, various
immune cells have been shown to produce and react to pro- and
anti-inflammatory cytokines in the inflamed CNS. The main
cytokines secreted by antigen-presenting cells, pathogenic CD4+
Th cell subsets and Tregs are shown. Potential cytokine targets for
therapy and drugs are indicated in red. TNFα is expressed by T
cells but also by microglia and macrophages. Its blocking has failed
in clinical MS trials possibly because it has also homeostatic effects
in the CNS and is important for remyelination. Other cytokine
inhibitors like ustekinumab, which targets the p40 subunit of IL-12
and IL-23, involved in the generation of pathogenic CD4+ Th cell
subsets has recently been tested in clinical trials and was
unexpectedly ineffective to reduce clinical relapses in MS patients.
Studies with neutralizing anti-GM-CSF (MOR103), anti-IL17
(secukinumab) or anti-IL2Rα antibodies (daclizumab) are ongoing
and show promising first result in the treatment of MS patients.
Blocking of maturation factors of B cells (BLys, APRIL, or in the
case of neuromyelitis optica IL-6Rα by tocilizumab) might be
another therapeutic approach worth following up.
APC = antigen-presenting cell; BAFF = B cell activation factor; CNS
= central nervous system; EAE = experimental autoimmune
encephalomyelitis; GM-CSF = granulocyte macrophage colony
stimulating factor; IFN = interferon; IL = interleukin; MS = multiple
sclerosis; TPath = pathogenic CD4+ Th cell subsets; Th = T helper
cell; TNF-α = tumour necrosis factor.α; Treg = regulatory T cell.
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poly I:C can stimulate cells in the CNS to produce IFN-β
[105]. To trace the cell type that mediates the “protective”
immune regulation of type I IFNs, mice lacking the type
I receptor (IFNAR) only in distinct cell populations were
used for EAE experiments [18]. This study revealed that
negative regulation of EAE disease severity by type I IFNs
relies on the presence of IFNAR on myeloid cells (includ-
ing monocytes, macrophages and microglia). Prinz and col-
leagues concluded that locally produced IFN-β within the
CNS acts on invading myeloid cells to attenuate autoim-
mune damage in the effector phase of EAE, and the IFNAR
pathway seems to be tightly regulated in these cells [106].
The therapeutic potential of CNS-restricted type I IFN in-
duction in MS is mainly unexplored. In fact, IFN-β drugs
are currently administered subcutaneously or intramuscu-
larly by MS patients and thereby probably act largely in the
periphery.
By this route, human recombinant IFN-β is mildly effective
in reducing the relapse rate in about half of patients with
MS, reducing relapse rates by about one-third [19]. Mul-
tiple molecular mechanisms by which IFN-β exerts its im-
munomodulatory functions in MS patients have been pro-
posed. They include inhibition of Th1 cell development
[20], deviation to Th2 cell responses [21], induction of
IL-10 [22], restoration of the disrupted blood-brain barrier
[23] and suppression of IFN-γ-induced class II major his-
tocompatibility complex (MHC) molecules on CNS cells
[24]. It is still not entirely clear which of these effects really
matter, but a combination of them likely contributes to the
clinical success of IFN-β administration.
Treatment failures
Administration of inhibitory cytokines: TGF-β and
IL-10
One method of cytokine-directed therapy is the application
of recombinant anti-inflammatory cytokines. However,
with the exception of IFN-β this approach was disappoint-
ing in the treatment of MS patients for different reasons
up to now. For example, systemic administration of trans-
forming growth factor (TGF)-β ameliorates EAE [25, 26]
and this very potent immunosuppressive cytokine is elev-
ated in the brains of individuals with MS [27]. However,
renal toxic effects were encountered in a small pilot human
trial to test the efficacy of administering TGF-β, and con-
sequently it has never been approved as a treatment for MS
[28]. Another phase II clinical trial testing IL-10, which is
an important suppressive cytokine as well, as a treatment in
MS patients was stopped due to lack of efficacy [29].
TNF-α blockers: what protects inflamed joints can be
harmful for the brain
TNF-α is one of the most widespread clinically targeted cy-
tokines. Its inhibition has also been considered as a therapy
for MS. TNF-α is produced by several cell types includ-
ing T cells, macrophages and microglia, and its receptors
TNF receptor 1 and 2 are ubiquitously expressed. TNF-
α is important in the control and containment of local in-
fections, but deregulated TNF-α production can be harm-
ful in the setting of sepsis and several other inflammatory
and autoimmune diseases. In (chronic progressive) MS pa-
tients, intrathecal TNF-α synthesis has been demonstrated,
and TNF-α levels in the CSF have been correlated with the
severity and progression of disease [30, 31]. In the mouse
model of MS, TNF-α blockade by antibodies or soluble
TNF receptors prevented or reversed disease [32, 33].
Surprisingly, however, drugs that block TNF-α, which are
beneficial in a number of diseases (including rheumatoid
arthritis, ankylosing spondylitis, psoriasis, and inflammat-
ory bowel disease) can cause the occurrence of prolonged
and more relapses in patients with MS [34, 35]. The reas-
ons for this worsening are still not fully understood. One
explanation might be that TNF-α may have protective
properties in the CNS and that TNF signalling is also im-
portant for remyelination [36, 37]. The failure of TNF-α in-
hibition to reduce clinical MS emphasises the fact that the
mechanism of tissue damage in disease-affected joints in
individuals with rheumatoid arthritis differs fundamentally
from that in the CNS of MS patients. It also teaches us that
cytokine functions can be complex and the sole presence of
a proinflammatory cytokine in the CSF of MS patients does
not necessarily mean that its inhibition results in a success-
ful treatment strategy. Furthermore, it illustrates that stud-
ies using current EAE models have to be interpreted care-
fully and can have limitations with regard to predicting
success in clinical trials [38].
It is of concern that new-onset MS-like demyelinating le-
sions as well as worsening of established MS following
exposure to anti-TNF-α agents for rheumatoid arthritis or
Crohn's disease have been reported [39, 40]. Moreover,
TNF-α blockers have been claimed to give rise to various
forms of demyelinating neuropathies [41]. Even though
these observations might in part be explained by shared ge-
netic susceptibility to autoimmune disorders including MS,
anti-TNF therapy might trigger and bring out inflammatory
demyelination disease in patients.
Atacicept: targeting B cell cytokines
Immunotherapies depleting B cell populations have been
found to slow disease progression in MS (anti-CD20: ritux-
imab and ocrelizumab) [42, 43]. However, targeting the
cytokines BlyS (B-lymphocyte stimulator) and APRIL (a
proliferation-inducing ligand), which are involved in B-
cell maturation, function and survival, has failed in MS pa-
tients. This can be concluded from a phase II safety and
efficacy trial of the BAFF (B cell activation factor) recept-
or fusion protein atacicept in patients with MS which had
to be halted owing to an increase in annualised relapse
rates [44]. The reasons for this disappointing result are un-
known. It is clear that atacicept targets B cells in differ-
ent developmental stages compared with other B cell-dir-
ected therapies like rituximab [45], but we have yet to learn
why rituximab halts disease progression whereas atacicept
drives relapses. As the role of B cells in MS pathogenes-
is remains largely enigmatic, we have a long way to go to
make sense of these findings.
Interleukin-12/interleukin-23: hitting two birds with
one stone
IL-12 and IL-23 are of particular interest in MS, because
they induce the differentiation of naïve CD4+ T cells into
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proinflammatory and, presumably, pathogenic T helper cell
populations. IL-12 and IL-23 are both produced mainly by
activated myeloid cells and bind to receptors that are ex-
pressed on lymphocytes. IL-12 is crucial for the differen-
tiation along a Th1 cell lineage, and IL-23 promotes and
stabilises IL-17 production by CD4+ T cell (Th17 cells)
[46]. IL-12 and IL-23 are heterodimers each composed of
a common subunit (p40), with either p35 (IL-12) or p19
(IL-23) as a unique chain [47]. The common p40 subunit
has been detected in MS lesions and levels in peripheral
blood mononuclear cells in MS patients have been correl-
ated with disease activity [48, 49]. The neutralisation of
p40 inhibits EAE in rodents and nonhuman primates [50].
Therefore there is considerable evidence that blocking the
p40 subunit would be beneficial to patients with MS.
Contrary to this expectation, neutralisation of p40 did not
inhibit disease activity in patients with MS. Two hundred
and forty-nine patients with relapsing-remitting MS were
treated with four different dosing regimens of ustekinumab
(anti-p40) or placebo for 19 weeks. The primary endpoint,
the cumulative number of new contrast-enhancing cranial
MR lesions, was not different between placebo and the
ustekinumab treatment arms [51]. It is not entirely clear
mechanistically why the results of the ustekinumab trial in
MS were negative. They are in conflict with the outcome of
studies of p40 blockade in other autoimmune diseases. For
example, ustekinumab effectively improved disease sever-
ity in patients with psoriasis and psoriatic arthritis [52, 53].
It also showed benefits in the treatment of moderate-to-
severe Crohn’s disease that was resistant to TNF antagon-
ists [54]. One explanation for its failure in MS might be that
IL-23 is maybe only important in the generation of patho-
genic T cells prior to disease onset or early during the dis-
ease course, and therefore ustekinumab was given too late.
It is also unclear if ustekinumab needs to act locally at the
site of CNS inflammation in MS patients and, if this is the
case, whether the drug penetrates into the CNS sufficiently
[55, 56].
In clinical development
Interleukin-17 inhibition
The rationale behind blockade of IL-23 stems from the
assumption that IL-23 is an important differentiation and
maintenance factor for Th17 cells and controls the produc-
tion of presumably pathogenic IL-17. IL-17 is a pleiotropic
cytokine that is the hallmark secreted protein of so-called
Th17 cells. IL-17A and IL-17F are two IL-17 family mem-
bers that are secreted by Th17 cells and share the same
IL-17 receptors that are broadly expressed by stromal cells.
In a deregulated autoimmune setting, IL-17 could recruit
neutrophils and macrophages and cause release of medi-
ators of local tissue destruction. Indeed, IL-17 has been
linked to several autoimmune diseases including psoriasis,
inflammatory bowel disease, rheumatoid arthritis and MS
[57].
In EAE, the contribution of IL-17 itself as well as of IL-22,
another cytokine produced by Th17 cells, to disease devel-
opment is controversial, as T cell-specific IL-17A overex-
pression and IL-17A, IL-17F or IL-22 inhibition had only a
minor impact [58, 59]. The results of the EAE studies raise
at least some scepticism about the biological importance
of IL-17 alone in autoimmune CNS inflammation. Never-
theless, in human MS, accumulation and up-regulation of
Th17 signature cytokines such as IL-17 in the CNS have
been reported [27, 60] and phase II clinical trials testing a
humanised antibody that targets IL-17A (secukinumab or
AIN457) are ongoing or have been completed [61] (clinic-
altrials.gov identifier: NCT01433250 and NCT01874340).
The results of the larger of these phase II trials including
380 patients and measuring the number of new gadolinium
T1 lesions in magnetic resonance imaging (MRI) as a
primary endpoint have not been published yet. Antibodies
that specifically neutralise IL-17 showed extremely good
therapeutic efficacy for the treatment of psoriasis [62], but
have failed to ameliorate Crohn’s disease [63], maybe be-
cause basal levels of IL-17 might be gut protective. This
again emphasises that the different disease setting matters,
and it will be interesting to learn about the final outcome of
secukinumab treatments in MS patients.
Humanised monoclonal antibodies against the IL-6
receptor and neuromyelitis optica
IL-6 is produced by various haematopoietic and nonhaema-
topoietic cells in response to tissue damage and infections.
It is a central mediator of the immune system, inducing the
acute phase response in the liver, fever and optimal T and
B cell effector responses to fight off pathogens. In particu-
lar, it is an important factor that induces the final differen-
tiation of B cells into antibody-secreting plasma cells [64].
Given the known functions of IL-6, targeting the bioactiv-
ity of this cytokine is a rational therapeutic approach for
the treatment of autoimmune diseases. An important con-
sideration for the design of IL-6 modulating therapies is
that the IL-6Rα chain occurs in a membrane-bound and sol-
uble form, and requires an accessory molecule glycopro-
tein 130 (gp130) for signal transduction. Tocilizumab is
a humanised antibody that is directed against the IL-6Rα
chains and allows for the targeting of both membrane-
bound forms, expressed on immune cells and hepatocytes,
and soluble forms of the receptor. Tocilizumab has efficacy
in the therapy of moderate-to-severe rheumatoid arthritis
[65, 66] and juvenile idiopathic arthritis [67], and is ap-
proved in Switzerland for these indications.
Neuromyelitis optica (NMO) is an inflammatory disease
affecting the optic nerve and spinal cord, in which
autoantibodies against aquaporin 4 water channel protein
located on astrocyte processes probably are pathogenic
[68]. As it is pathogenetically different from MS, some
MS treatments, such as IFN-β, natalizumab and oral fin-
golimod, can even exacerbate NMO [69]. For example,
IFN-β was tried as a therapeutic agent but it soon became
apparent that IFN-β treatment can worsen NMO and induce
severe relapses [70–73].
Recent studies have suggested that IL-6 could play a role
in NMO pathogenesis by contributing to the persistence
of anti-aquaporin-4 antibody-producing plasmablasts in pa-
tients with NMO [74]. Furthermore, increased IL-6 levels
have been measured in serum and CSF of patients with
NMO compared with those with MS [75, 76]. The relative
infrequency of NMO, in contrast to MS, has impeded large
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clinical treatment trials for this disease. However, several
cases and small patient series have been reported, which
support the concept that IL-6-targeted therapy with tocili-
zumab could have a favourable effect in NMO patients who
have failed to respond to other therapies [77–79]. For ex-
ample, Araki and colleagues treated 7 patients with anti-
aquaporin-4 positive NMO with tocilizumab for 1 year
who had previously been treated with oral prednisolone
and immunosuppressants such as azathioprine. The authors
reported that the annualised relapse rate decreased in these
patients from 2.9 to 0.4 [80].
GM-CSF: detrimental in autoimmune tissue
inflammation, needed to keep the lungs clean
GM-CSF (granulocyte-macrophage colony-stimulating
factor) is another cytokine that has been associated with the
progression of inflammatory diseases such as rheumatoid
arthritis and MS. GM-CSF receptors are heterodimers con-
sisting of a ligand-specific α-subunit (GM-CSFR-α) and a
β-chain subunit that is shared with other cytokine recept-
ors and is responsible for cell signalling. GM-CSF was first
characterised by its ability to cause the differentiation of
myeloid cells into granulocytic, macrophage and dendritic
cell colonies in vitro. Clinicians take advantage of this ef-
fect and use it in patients to increase myeloid cell expan-
sion and differentiation after chemotherapy-induced my-
elosuppression. Exacerbations of established rheumatoid
arthritis have been reported in patients who received GM-
CSF as supportive therapy [81, 82], which already points
to an involvement of GM-CSF in autoimmune joint inflam-
mation.
GM-CSF deficient mice are protected from myocarditis
[83], experimental models of arthritis [84] and EAE [85,
86]. In line with these studies, experiments in mice have
shown that neutralising antibodies against GM-CSF ameli-
orate EAE [87, 88]. Activated Th cells, the main source
of GM-CSF during inflammation, do not themselves re-
spond to GM-CSF. They therefore must communicate with
GM-CSF-sensitive cell types to mediate pathology in EAE.
Tissue-invading monocytes, which give rise to inflammat-
ory antigen-presenting cells, are responsible for CNS tissue
damage [89]. Additionally, these cells are highly GM-CSF
responsive and represent a likely candidate for the GM-
CSF-responder cell mediating demyelination during exper-
imental autoimmunity [107].
In MS patients, elevated levels of GM-CSF in the CSF as
compared to controls have been reported [90, 91], and Th
cells from the CSF of MS patients have higher expression
levels of GM-CSF ex vivo compared with control patients
[92]. Furthermore, an association of GM-CSF expression
by human Th cells with MS disease severity has been pro-
posed [93], making this cytokine a promising therapeut-
ic target in MS. A completed randomised, double blind,
placebo-controlled phase Ib study including 31 patients
with either relapsing-remitting or secondary progressive
MS evaluated the safety of MOR103, a recombinant human
IgG1 antibody against GM-CSF (clinicaltrials.gov identi-
fier: NCT01517282). Data on the efficacy of MOR103 in
MS are not available up to now. However, the same anti-
body was reported to be well tolerated and to show prelim-
inary evidence of efficacy in patients with active rheum-
atoid arthritis (phase Ia/IIb) [94] and GM-CSF receptor-α
blockade with mavrilimumab reduced disease activity in
patients with rheumatoid arthritis (phase I and II) [95, 96].
Of note, neutralising anti-GM-CSF antibodies can impair
alveolar macrophage function and are found in the majority
of patients with acquired pulmonary alveolar proteinosis,
a rare lung disease [97]. Burmester and colleagues did not
observe changes in pulmonary parameters, but this needs to
be closely monitored over longer time periods during clin-
ical trials.
IL-2 receptor α-chain (CD25) blockade: daclizumab
IL-2 is a T cell growth factor that has long been known as
an important survival and proliferation signal for T cells
[3]. Unexpectedly, mice deficient in IL-2 or components
of the IL-2 receptor succumb to an aggressive, lymphop-
roliferative autoimmune syndrome [98]. Later studies re-
vealed that IL-2 is also a critical factor for CD4+ regulatory
T cells (Foxp3+ Tregs) to be able to terminate overshoot-
ing autoreactive T cell responses [99, 100]. Daclizumab,
a humanised monoclonal anti-IL-2Rα (also called CD25)
antibody has been tested in several clinical trials in MS
patients based on the rationale that blocking the high-af-
finity IL-2 receptor would prevent the expansion of autore-
active T lymphocytes [101]. Results of mechanistic studies
showed that daclizumab acts at least in part by expanding a
regulatory (CD56bright NK) immune cell population [102].
Previous Phase I/II clinical trials have demonstrated con-
sistent and significant beneficial effects of daclizumab on
MRI and clinical disease measures of MS. Daclizumab
seems to be generally well tolerated. However, serious ad-
verse events have been reported and include infections,
skin reactions, abnormal liver function tests and autoim-
mune conditions (affecting liver and kidney). The DECIDE
phase III trial (clinicaltrials.gov identifier: NCT01064401)
compared daclizumab, which is injected subcutaneously
once a month, and IFNβ-1a in patients with relapsing-
remitting MS [103]. It was reported that daclizumab re-
duced the annualised relapse rate by 45% compared with
IFNβ-1a. In addition, 54% fewer new or enlarging CNS
lesions were detected by MRI after nearly two years of
daclizumab treatment, compared with those patients inject-
ing IFNβ-1a. Applications for the approval of daclizumab
(high-yield process, DAC HYP) for the treatment of pa-
tients with MS are currently under review by agencies both
in Europe and the USA.
Conclusions and future perspectives
Cytokines have a major role in driving CNS inflammation
in MS patients. Therefore, blockade of proinflammatory
cytokines remains an attractive avenue for MS therapy. In
contrast to rheumatoid arthritis and inflammatory bowel
disease, where TNF-α is currently one of the key targets
for treatment, TNF-α inhibitors worsen MS. This may re-
flect that cytokine networks likely differ between autoim-
mune inflammatory diseases and tissue-location matters.
The CNS appears to be unique in its vulnerability to an
autoimmune milieu, where proinflammatory cytokines and
immune cells are let loose. Furthermore, it has been pro-
posed that cytokines are also involved in homeostatic brain
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functions like re-/myelination, which poses a challenge for
cytokine-inhibiting therapies. Some blocking monoclonal
antibodies that are directed against cytokine/receptors
within the brain and spinal cord might not penetrate suf-
ficiently, and approaches for the optimised delivery to the
inflammatory CNS foci need to be further explored. It is
still puzzling that one specific cytokine-directed therapy
may be detrimental rather than protective even if the same
target organ, the CNS, is affected. This is illustrated by
the clinical exacerbations that have been observed after the
use of IFN-β in NMO patients, probably because a dif-
ferent immune pathomechanism predominates compared
with MS. Indeed, a characteristic feature of MS is its clin-
ical and immunopathological heterogeneity and the exist-
ence of multiple phases of disease, during the course of
which the cytokine production pattern and requirements for
a sustained autoimmune tissue inflammation may change.
Another important question that remains is the safety of
long-term treatments, that could be complicated by re-ac-
tivations of potentially harmful latent infections or im-
paired lung function for example in the case of GM-CSF
inhibition. Lessons from clinical trials testing cytokine-dir-
ected therapies in various autoimmune diseases including
MS teach us that all these factors need to be considered.
Despite these limitations, the development of anti-cytokine
therapies still holds promise also for CNS inflammatory
diseases, and their use will certainly improve our under-
standing of their pathogenesis.
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Figures (large format)
Figure 1
Key cytokines in the pathogenesis of multiple sclerosis.
In patients with MS and in its experimental models EAE, various immune cells have been shown to produce and react to pro- and anti-
inflammatory cytokines in the inflamed CNS. The main cytokines secreted by antigen-presenting cells, pathogenic CD4+ Th cell subsets and
Tregs are shown. Potential cytokine targets for therapy and drugs are indicated in red. TNFα is expressed by T cells but also by microglia and
macrophages. Its blocking has failed in clinical MS trials possibly because it has also homeostatic effects in the CNS and is important for
remyelination. Other cytokine inhibitors like ustekinumab, which targets the p40 subunit of IL-12 and IL-23, involved in the generation of
pathogenic CD4+ Th cell subsets has recently been tested in clinical trials and was unexpectedly ineffective to reduce clinical relapses in MS
patients. Studies with neutralizing anti-GM-CSF (MOR103), anti-IL17 (secukinumab) or anti-IL2Rα antibodies (daclizumab) are ongoing and
show promising first result in the treatment of MS patients. Blocking of maturation factors of B cells (BLys, APRIL, or in the case of neuromyelitis
optica IL-6Rα by tocilizumab) might be another therapeutic approach worth following up.
APC = antigen-presenting cell; BAFF = B cell activation factor; CNS = central nervous system; EAE = experimental autoimmune
encephalomyelitis; GM-CSF = granulocyte macrophage colony stimulating factor; IFN = interferon; IL = interleukin; MS = multiple sclerosis; TPath
= pathogenic CD4+ Th cell subsets; Th = T helper cell; TNF-α = tumour necrosis factor.α; Treg = regulatory T cell.
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